A5056467131- Colorectal Cancer Treatments and Studies
- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Blood disorders and treatments
- Pancreatic and Hepatic Oncology Research
- Chemotherapy-induced organ toxicity mitigation
- Adolescent and Pediatric Healthcare
- Biochemical and Molecular Research
- Infant Development and Preterm Care
- Cancer therapeutics and mechanisms
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Lanthanide and Transition Metal Complexes
- Lung Cancer Research Studies
- Cytomegalovirus and herpesvirus research
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Herpesvirus Infections and Treatments
- HIV/AIDS drug development and treatment
- Sarcoma Diagnosis and Treatment
- Children's Physical and Motor Development
- Drug-Induced Hepatotoxicity and Protection
St. Jude Children's Research Hospital
2022-2025
Institut Claudius Regaud
2020-2022
Université Toulouse III - Paul Sabatier
2020-2022
Inserm
2020-2022
Centre de Recherche en Cancérologie de Toulouse
2020-2022
Université de Toulouse
2021
Centre National de la Recherche Scientifique
2021
Institut universitaire du cancer de Toulouse Oncopole
2021
Sorbonne Université
2013
Thiopurines such as mercaptopurine (MP) are widely used to treat acute lymphoblastic leukemia (ALL). Thiopurine-S-methyltransferase (TPMT) and Nudix hydrolase 15 (NUDT15) inactivate thiopurines, no-function variants associated with drug-induced myelosuppression. Dose adjustment of MP is strongly recommended in patients intermediate or complete loss activity TPMT NUDT15. However, the extent dosage reduction for both enzymes currently not clear. dosages during maintenance were collected from...
ETV6::RUNX1 is the most common fusion gene in childhood acute lymphoblastic leukemia (ALL) associated with favorable prognosis, but optimal therapy for this subtype remains unclear. Profiling genomic and pharmacological landscape of 194 pediatric ALL cases, we uncover two transcriptomic clusters, C1 (61%) C2 (39%). Compared to C1, features higher white blood cell counts younger age at diagnosis, as well better early treatment responses. Pharmacologically, more sensitive thiopurines...
Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre-analytical recommendations for determining U and dihydrouracil (UH2 ) concentrations, as they are essential reliable DPD-deficiency testing.U UH2 concentrations were collected from 14 hospital laboratories. Stability whole blood after centrifugation, type of anticoagulant...
Maillard, Maud; Gong, Li; Nishii, Rina; Yang, Jun J.; Whirl-Carrillo, Michelle; Klein, Teri E. Author Information
Tyrosine kinase inhibitors pazopanib and sunitinib are both used to treat advanced renal cell carcinoma but expose patients an increased risk of hepatotoxicity. We have previously identified two aldehyde derivatives for (P-CHO S-CHO, respectively) in liver microsomes. In this study, we aimed decipher their role hepatotoxicity by treating HepG2 HepaRG hepatic lines with these evaluating viability, mitochondrial dysfunction, oxidative stress accumulation. Additionally, plasma concentrations...
Nudix hydrolase 15 (NUDT15) deficiency is strongly associated with thiopurine‐induced myelosuppression. Currently, testing for NUDT15 based on the genotyping of most frequent and clinically characterized no‐function variants, that is, * 2 , 3 9 . The Hispanic/Latino‐predominant variant 4 (p.R139H) classified as “uncertain function” by Clinical Pharmacogenetics Implementation Consortium, because insufficient data to ascertain its clinical actionability. In this study, we evaluated association...
Hepatotoxicity is an important concern for nearly 40% of the patients treated with trabectedin advanced soft tissue sarcoma (ASTS). The mechanisms underlying these liver damages have not yet been elucidated but they suggested to be related production reactive metabolites. aim this pharmacogenetic study was identify genetic variants pharmacokinetic genes such as CYP450 and ABC drug transporters that could impair metabolism in hepatocytes. Sixty-three ASTS from TSAR clinical trial...
Le 5-fluoro-uracile (5-FU) et la capécitabine appartiennent à classe des fluoropyrimidines, molécules cytotoxiques anciennes mais encore indispensables pour le traitement de nombreuses tumeurs solides (côlon rectum, oropharynx, seins, ovaires). Ces peuvent entraîner effets indésirables, principalement hématologiques digestifs. Une causes toxicité fluoropyrimidines est déficit l’activité dihydropyrimidine déshydrogénase (DPD), une enzyme impliquée dans leur inactivation élimination. forte...